The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma
Open accessAbstract
The identification of many tumor-associated epitopes as nonmutated “self” Ags led to the hypothesis that the induction of large numbers of self/tumor Ag-specific T cells would be prevented because of central and peripheral tolerance. We report in this study on vaccination efforts in 95 HLA-A*0201 patients at high risk for recurrence of malignant melanoma who received prolonged immunization with the “anchor-modified” synthetic peptide, gp100209–217(210M). Vaccination using this altered peptide immunogen was highly effective at inducing large numbers of self/tumor-Ag reactive T cells in virtually every patient tested, with levels as high as 42% of all CD8+ T cells assessed by tetramer analysis. From 1 to 10% of all CD8+ cells were tumor-Ag reactive in 44% of patients and levels >10% were generated in 17% of patients. These studies were substantiated using the ELISPOT assay and a bulk cytokine release assay. Although our data regarding “tumor escape” were inconclusive, some patients had growing tumors that expressed Ag and HLA-A*0201 in the presence of high levels of antitumor T cells. There was no difference in the levels of antitumor Ag-specific T cells in patients who recurred compared with those that remained disease-free. Thus, the mere presence of profoundly expanded numbers of vaccine-induced, self/tumor Ag-specific T cells cannot by themselves be used as a “surrogate marker” for vaccine efficacy. Further, the induction of even high levels of antitumor T cells may be insufficient to alter tumor progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takeda, K., Kaisho, T., & Akira, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141126 · Cited by 6,143
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Self-citationCancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Self-citationRosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,784
Self-citationDudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,639
Self-citationPhan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575 · cited 1×
“The blockade of a negative costimulatory molecule, CTLA-4, using a mAb has been shown to result in cancer regression in patients with metastatic melanoma (34).”
BackgroundSelf-citationGattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050732 · Cited by 1,061
Self-citationNatural selection of tumor variants in the generation of “tumor escape” phenotypes
Khong, H. T., & Restifo, N. P. (2002) · Nature Immunology · doi:10.1038/ni1102-999 · Cited by 1,058
Self-citationOverwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth-Dreese, F. A., Dellemijn, T. A., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 925
Self-citationParkhurst, M. R., Salgaller, M. L., Southwood, S., Robbins, P. F., Sette, A., Rosenberg, S. A., & Kawakami, Y. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.6.2539 · Cited by 556
Self-citationAbeyama, K., Stern, D. M., Ito, Y., Kawahara, K.-I., Yoshimoto, Y., Tanaka, M., Uchimura, T., Ida, N., Yamazaki, Y., Yamada, S., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522782 · Cited by 547
Waldmann, T. (2001) · Immunity · doi:10.1016/s1074-7613(09)00091-0 · Cited by 434
Structure and function of thrombomodulin: a natural anticoagulant
Dittman, W., & Majerus, P. (1990) · Blood · doi:10.1182/blood.v75.2.329.329 · Cited by 411
Marshall, J. L., Hoyer, R. J., Toomey, M. A., Faraguna, K., Chang, P., Richmond, E., Pedicano, J. E., Gehan, E., Peck, R. A., Arlen, P., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.23.3964 · Cited by 357
Eder, J. P., Kantoff, P. W., Röper, K., Xu, G., Bubley, G. J., Boyden, J., Gritz, L. R., Mazzara, G. P., Oh, W. K., Arlen, P. M., et al. (2000) · PubMed · Cited by 294
Lee, P., Wang, F., Kuniyoshi, J., Rubio, V., Stuge, T., Groshen, S., Gee, C., Lau, R., Jeffery, G., Margolin, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3836 · Cited by 244
Wang, F., Bade, E., Kuniyoshi, C., Spears, L., Jeffery, G., Marty, V., Groshen, S. G., & Weber, J. S. (1999) · PubMed · Cited by 242
Germeau, C., Ma, W., Schiavetti, F., Lurquin, C., Henry, E., Vigneron, N., Brasseur, F., Lethé, B., De Plaen, E., Velu, T., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041379 · Cited by 232
Cutting Edge: Extracellular High Mobility Group Box-1 Protein Is a Proangiogenic Cytokine
Mitola, S., Belleri, M., Urbinati, C., Coltrini, D., Sparatore, B., Pedrazzi, M., Melloni, E., & Presta, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.12 · Cited by 229
Slingluff, C. L., Yamshchikov, G. V., Neese, P. Y., Galavotti, H., Eastham, S., Engelhard, V. H., Kittlesen, D. J., Deacon, D. H., Hibbitts, S., Grosh, W. W., et al. (2001) · PubMed · Cited by 229
Coulie, P. G., Karanikas, V., Colau, D., Lurquin, C., Landry, C., Marchand, M., Dorval, T., Brichard, V., & Boon, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161260098 · Cited by 220
Heteroclitic Immunization Induces Tumor Immunity
Dyall, R., Bowne, W. B., Weber, L. W., LeMaoult, J., Szabo, P., Moroi, Y., Piskun, G., Lewis, J. J., Houghton, A. N., & Nikolić-Žugić, J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.9.1553 · Cited by 200
Assays for monitoring cellular immune responses to active immunotherapy of cancer.
Clay, T. M., Hobeika, A. C., Mosca, P. J., Lyerly, H. K., & Morse, M. A. (2001) · PubMed · Cited by 171
Scheibenbogen, C., Schmittel, A. H., Keilholz, U., Allgäuer, T., Hofmann, U., Max, R., Thiel, E., & Schadendorf, D. (2000) · Journal of Immunotherapy · doi:10.1097/00002371-200003000-00012 · Cited by 131
Animal models of tumor immunity, immunotherapy and cancer vaccines
Ostrand‐Rosenberg, S. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.01.003 · Cited by 123
Contrasting Roles of IL-2 and IL-15 in the Life and Death of Lymphocytes
Waldmann, T. A., Dubois, S. P., & Tagaya, Y. (2001) · Immunity · doi:10.1016/s1074-7613(01)00093-0 · Cited by 115
Ha, P., Schwarz, S. L., Wunderlich, J. R., & Rosenberg, S. A. (1998) · PubMed · Cited by 110
Self-citationSmith, J. W., Walker, E., Fox, B. A., Haley, D. P., Wisner, K. P., Doran, T., Fisher, B. K., Justice, L., Wood, W. A., Vetto, J. T., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.020 · Cited by 110
Schaed, S. G., Klimek, V. M., Panageas, K. S., Musselli, C., Butterworth, L., Hwu, W., Livingston, P. O., Williams, L. J., Lewis, J. J., Houghton, A. N., et al. (2002) · PubMed · Cited by 107
Evidence of Human Thrombomodulin Domain as a Novel Angiogenic Factor
Shi, C., Shi, G.-Y., Chang, Y.-S., Han, H.-S., Kuo, C., Liu, C., Huang, H., Chang, Y., Chen, P.-S., & Wu, H. (2005) · Circulation · doi:10.1161/01.cir.0000160364.05405.b5 · Cited by 86
Romero, P. J., Cerottini, J., & Speiser, D. E. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0473-9 · Cited by 74
Powell, D. J., & Rosenberg, S. A. (2003) · Journal of Immunotherapy · doi:10.1097/00002371-200401000-00004 · Cited by 71
Self-citationEndostatin Signaling and Regulation of Endothelial Cell–Matrix Interactions
Wickström, S. A., Alitalo, K. K., & Keski‐Oja, J. (2005) · Advances in cancer research · doi:10.1016/s0065-230x(05)94005-0 · Cited by 55
MONITORING IMMUNE RESPONSES IN CANCER PATIENTS RECEIVING TUMOR VACCINES
Walker, E., & Disis, M. L. (2003) · International Reviews of Immunology · doi:10.1080/08830180305226 · Cited by 31
Chan, S.-H., Chen, J.-H., Li, Y., Lin, L.-J., & Tsai, L. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.09.015 · Cited by 28
Manjili, M. H., Arnouk, H., Knutson, K. L., Kmieciak, M., Disis, M. L., Subjeck, J. R., & Kazim, A. L. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9044-4 · Cited by 26
Peptide vaccine trials for melanoma: preclinical background and clinical results
Talebi, T. N., & Weber, J. S. (2003) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.09.007 · Cited by 22
Recent advances in tumour antigen‐specific therapy: In vivo veritas
Mahnke, Y. D., Speiser, D. E., Luescher, I. F., Cerottini, J., & Romero, P. J. (2004) · International Journal of Cancer · doi:10.1002/ijc.20572 · Cited by 14
Rosenberg, S. A., & Restifo, N. P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.4511-a · Cited by 3
Self-citation
Cited by
T cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Self-citationDewan, M. Z., Galloway, A. E., Kawashima, N., Dewyngaert, J. K., Babb, J. S., Formenti, S. C., & Demaria, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0265 · Cited by 1,678
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
Self-citationAnti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,437
Metadata
- Authors
- Rosenberg, S. A., Sherry, R. M., Morton, K. E., Scharfman, W. J., Yang, J. C., Topalian, S. L., Royal, R. E., Kammula, U., Restifo, N. P., Hughes, M. S., Schwartzentruber, D., Berman, D. M., Schwarz, S. L., Ngo, L. T., Mavroukakis, S. A., White, D. E., & Steinberg, S. M.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-11-01
- Volume
- 175
- Issue
- 9
- Pages
- 6169-6176
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2103018035
- Cited by
- 465
- References
- 39
- FWCI
- 11.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.